Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

tyrphostin AG957

Known as: AG957, Tyrphostin AG 957, AG 957 
A member of the tyrphostin family of tyrosine kinase inhibitors that selectively inhibits human p210 tyrosine kinase activity. (NCI)
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Benzylidene CompoundsNitrilesTyrphostins
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Inhibition of fast sodium current in rabbit ventricular myocytes by protein tyrosine kinase inhibitors
The present study investigated the effects of protein tyrosine kinase inhibitors on the fast sodium current (INa) in rabbit… 
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 6
2002
2002
Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
AG957 (NSC 654705) is a tyrphostin tyrosine kinase inhibitor that has been demonstrated previously to induce growth arrest in… 
2002
2002
In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines
Abstract Purpose.NSC 680410, the novel adamantyl ester of AG957, an inhibitor of the p210bcr/abl tyrosine kinase (CML, Ph+) and… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2001
Review
2001
Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR.
Clinical circumvention of multidrug resistance (MDR) is a Sisyphian task faced in the treatment of many cancers. Identification… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2001
Highly Cited
2001
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
STI571 (formerly CGP57148) and AG957 are small molecule inhibitors of the protein tyrosine kinase (PTK) p145(abl) and its… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2000
Highly Cited
2000
Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
The tyrphostin AG957 (NSC 654705) inhibits p210bcr/abl, the transforming kinase responsible for most cases of chronic myelogenous… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
1999
1999
Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
The hallmark of chronic myelogenous leukemia (CML) is the Philadelphia (Ph) chromosome that fuses genetic sequences of the BCR… 
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
1998
1998
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic…
Abnormal β1 integrin receptor function may contribute to the continuous proliferation and abnormal circulation of malignant… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
1996
1996
Altered physical state of p21bcr—abl in tyrphostin AG957-treated K562 cells
AG957 is a tyrosine kinase antagonist which prior studies had shown inhibits p2106bcr abl tyrosine kinase activity and K562… 
Highly Cited
1994
Highly Cited
1994
Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
We have examined a series of tyrosine kinase inhibitors structurally related to erbstatin (tyrphostins) for inhibition of p210bcr… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE